{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:23:02Z","timestamp":1793733782253,"version":"4.6.1"},"reference-count":157,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Phytomedicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.phymed.2026.158065","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:53:44Z","timestamp":1773302024000},"page":"158065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Plant-derived natural compounds targeting drug resistance in ovarian cancer: Molecular mechanisms and therapeutic perspectives"],"prefix":"10.1016","volume":"155","author":[{"given":"Qiang","family":"Ao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7661-5923","authenticated-orcid":false,"given":"Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phymed.2026.158065_bib0001","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13048-025-01677-4","article-title":"Premature ovarian insufficiency restoration after chemotherapy: current achievements and future prospects on its treatment or management","volume":"18","author":"Aboutalebi","year":"2025","journal-title":"J. Ovarian. Res."},{"key":"10.1016\/j.phymed.2026.158065_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11864-023-01166-0","article-title":"Antibody-drug conjugates in gynecologic cancers","volume":"25","author":"Anastasio","year":"2024","journal-title":"Curr. Treat. Options. Oncol."},{"key":"10.1016\/j.phymed.2026.158065_bib0003","doi-asserted-by":"crossref","first-page":"972","DOI":"10.6004\/jnccn.2022.0047","article-title":"NCCN Guidelines\u00ae insights: ovarian cancer, version 3.2022","volume":"20","author":"Armstrong","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.phymed.2026.158065_bib0004","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.semcancer.2021.05.023","article-title":"Interference between copper transport systems and platinum drugs","volume":"76","author":"Arnesano","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.phymed.2026.158065_bib0005","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(23)00396-0","article-title":"Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial","volume":"24","author":"Aronson","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phymed.2026.158065_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106427","article-title":"New trends in synthetic drugs and natural products targeting 20S proteasomes in cancers","volume":"133","author":"Atta","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.phymed.2026.158065_bib0007","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/ijc.34165","article-title":"The prevalence of mismatch repair deficiency in ovarian cancer: a systematic review and meta-analysis","volume":"151","author":"Atwal","year":"2022","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.phymed.2026.158065_bib0008","doi-asserted-by":"crossref","first-page":"9236","DOI":"10.3390\/ijms24119236","article-title":"Effects of flavonoids on cancer, cardiovascular and neurodegenerative diseases: role of NF-\u03bab signaling pathway","volume":"24","author":"Barreca","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phymed.2026.158065_bib0009","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phymed.2026.158065_bib178","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s13046-021-01995-7","article-title":"Natural product triptolide induces GSDME-mediated pyroptosis in head and neck cancer through suppressing mitochondrial hexokinase-\u0399\u0399","volume":"40","author":"Cai","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.phymed.2026.158065_bib0010","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.3390\/ijms22073403","article-title":"Metalloproteinases in ovarian cancer","volume":"22","author":"Carey","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phymed.2026.158065_bib0011","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s43587-023-00524-9","article-title":"A drug-like molecule engages nuclear hormone receptor DAF-12\/FXR to regulate mitophagy and extend lifespan","volume":"3","author":"Chamoli","year":"2023","journal-title":"Nat. Aging"},{"key":"10.1016\/j.phymed.2026.158065_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101062","article-title":"The role of ABCC10\/MRP7 in anti-cancer drug resistance and beyond","volume":"73","author":"Chen","year":"2024","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.phymed.2026.158065_bib0013","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00262-022-03238-w","article-title":"Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer","volume":"72","author":"Chen","year":"2023","journal-title":"Cancer Immunol. Immunther."},{"key":"10.1016\/j.phymed.2026.158065_bib0014","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.4149\/neo_2022_220414N410","article-title":"Resveratrol reduces lactate production and modifies the ovarian cancer immune microenvironment","volume":"69","author":"Chen","year":"2022","journal-title":"Neoplasma"},{"key":"10.1016\/j.phymed.2026.158065_bib0015","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/biomedicines13010168","article-title":"Immunotherapy in recurrent ovarian cancer","volume":"13","author":"Chen","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.phymed.2026.158065_bib0016","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.3390\/ijms25073904","article-title":"Hinokitiol inhibits breast cancer cells In vitro stemness-progression and self-renewal with apoptosis and autophagy modulation via the CD44\/Nanog\/SOX2\/Oct4 pathway","volume":"25","author":"Chiang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phymed.2026.158065_bib0017","doi-asserted-by":"crossref","first-page":"7982","DOI":"10.3390\/ijms25147982","article-title":"Identification and validation of new DNA-PKcs inhibitors through high-throughput virtual screening and experimental verification","volume":"25","author":"Dai","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phymed.2026.158065_bib0018","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance Olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phymed.2026.158065_bib0019","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.3390\/cells9092114","article-title":"Hedgehog signaling and truncated GLI1 in cancer","volume":"9","author":"Doheny","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.phymed.2026.158065_bib0020","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1158\/1078-0432.CCR-23-2249","article-title":"Olaparib plus Durvalumab, with or without Bevacizumab, as treatment in PARP inhibitor-na\u00efve platinum-sensitive relapsed ovarian cancer: a phase II multi-cohort study","volume":"30","author":"Drew","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phymed.2026.158065_bib0021","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1089\/jir.2013.0059","article-title":"The serine protease granzyme B as an inflammatory marker, in relation to the insulin receptor cleavage in human obesity and type 2 diabetes mellitus","volume":"34","author":"El Mesallamy","year":"2014","journal-title":"J. Interferon. Cytokine Res."},{"key":"10.1016\/j.phymed.2026.158065_bib0023","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41568-019-0156-2","article-title":"Unmasking senescence: context-dependent effects of SASP in cancer","volume":"19","author":"Faget","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phymed.2026.158065_bib0024","article-title":"CCN1 Enhances tumor immunosuppression through collagen-mediated chemokine secretion in pancreatic cancer","volume":"12","author":"Fan","year":"2025","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.phymed.2026.158065_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100586","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials","volume":"7","author":"Filis","year":"2022","journal-title":"ESMo Open."},{"key":"10.1016\/j.phymed.2026.158065_bib175","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006070","article-title":"BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors","volume":"11","author":"Fu","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.phymed.2026.158065_bib0026","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1200\/JCO-24-02589","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline update","volume":"43","author":"Gaillard","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phymed.2026.158065_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166780","article-title":"SETD7 promotes metastasis of triple-negative breast cancer by YY1 lysine methylation","volume":"1869","author":"Gao","year":"2023","journal-title":"Biochim. Biophys. Acta Mol. Basis. Dis."},{"key":"10.1016\/j.phymed.2026.158065_bib0029","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s40265-023-01934-0","article-title":"Treatment of ovarian cancer beyond PARP inhibition: current and future options","volume":"83","author":"Garg","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.phymed.2026.158065_bib0030","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41571-024-00937-4","article-title":"Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach","volume":"21","author":"Ghisoni","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phymed.2026.158065_bib0031","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1158\/1078-0432.CCR-23-1079","article-title":"A B7-H4-targeting antibody-drug conjugate shows antitumor activity in PARPi and platinum-resistant cancers with B7-H4 expression","volume":"30","author":"Gitto","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phymed.2026.158065_bib0032","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241814186","article-title":"Base excision repair: mechanisms and impact in biology, disease, and medicine","volume":"24","author":"Gohil","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phymed.2026.158065_bib0033","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/ijgc-2020-001633","volume":"31","author":"Gonzalez Martin","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.phymed.2026.158065_bib0034","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/s42255-019-0122-z","article-title":"Cardiac glycosides are broad-spectrum senolytics","volume":"1","author":"Guerrero","year":"2019","journal-title":"Nat. Metab."},{"key":"10.1016\/j.phymed.2026.158065_bib0035","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.3390\/cancers12092398","article-title":"Impact of ERCC1, XPF and DNA polymerase \u03b2 expression on platinum response in patient-derived ovarian cancer xenografts","volume":"12","author":"Guffanti","year":"2020","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.phymed.2026.158065_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2023.112324","article-title":"The mechanism of copper transporters in ovarian cancer cells and the prospect of cuproptosis","volume":"247","author":"Guo","year":"2023","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.phymed.2026.158065_bib0037","article-title":"Editorial: advances of novel approaches to enhance therapeutic efficacy and safety in human solid cold tumor","volume":"15","author":"Guo","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phymed.2026.158065_bib0039","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3390\/pharmaceutics14040844","article-title":"Iron oxide nanoparticles-plant insignia synthesis with favorable biomedical activities and less toxicity, in the \u201cera of the-green\u201d: a systematic review","volume":"14","author":"Hamdy","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.phymed.2026.158065_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.138773","article-title":"Insights into the genetic and epigenetic mechanisms governing X-chromosome-linked-miRNAs expression in cancer; a step-toward ncRNA precision","volume":"289","author":"Hamdy","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.phymed.2026.158065_bib0041","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012541","article-title":"Cytotoxic T cell expression of leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) in viral Hepatitis C-mediated hepatocellular carcinoma","volume":"23","author":"Hammad","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phymed.2026.158065_bib0042","doi-asserted-by":"crossref","first-page":"15349","DOI":"10.1007\/s00432-023-05313-w","article-title":"Monocytes subsets altered distribution and dysregulated plasma hsa-miR-21-5p and hsa-miR-155-5p in HCV-linked liver cirrhosis progression to hepatocellular carcinoma","volume":"149","author":"Hammad","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.phymed.2026.158065_bib0043","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920967241","article-title":"Prognostic impact of tumor-infiltrating lymphocytes in high grade serous ovarian cancer: a systematic review and meta-analysis","volume":"12","author":"Hao","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.phymed.2026.158065_bib0044","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310960","article-title":"Potentiation of cisplatin cytotoxicity in resistant ovarian cancer SKOV3\/cisplatin cells by quercetin pre-treatment","volume":"24","author":"Hasan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phymed.2026.158065_bib0045","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3390\/ijms26020799","article-title":"Re-sensitization of resistant ovarian cancer SKOV3\/CDDP cells to cisplatin by curcumin pre-treatment","volume":"26","author":"Hasan","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phymed.2026.158065_bib0046","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s10517-022-05626-9","article-title":"Suppression of the antioxidant system and PI3K\/akt\/mTOR signaling pathway in cisplatin-resistant cancer cells by quercetin","volume":"173","author":"Hasan","year":"2022","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.phymed.2026.158065_bib0047","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3390\/medicina59030544","article-title":"Ovarian cancer-insights into platinum resistance and overcoming it","volume":"59","author":"Havasi","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.phymed.2026.158065_bib0048","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1111\/cas.14675","article-title":"Enhanced anti-tumor effects of the PD-1 blockade combined with a highly absorptive form of curcumin targeting STAT3","volume":"111","author":"Hayakawa","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.phymed.2026.158065_bib0049","first-page":"2612","article-title":"Harmine suppresses breast cancer cell migration and invasion by regulating TAZ-mediated epithelial-mesenchymal transition","volume":"12","author":"He","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.phymed.2026.158065_bib0050","article-title":"Cytoplasmic retention of a nucleocytoplasmic protein TBC1D3 by microtubule network is required for enhanced EGFR signaling","volume":"9","author":"He","year":"2014","journal-title":"PLoS. One"},{"key":"10.1016\/j.phymed.2026.158065_bib0051","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40265-023-01834-3","article-title":"Mirvetuximab Soravtansine: first approval","volume":"83","author":"Heo","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.phymed.2026.158065_bib0052","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1002\/ptr.7866","article-title":"Natural products targeting signaling pathways associated with regulated cell death in gastric cancer: recent advances and perspectives","volume":"37","author":"Hu","year":"2023","journal-title":"PhytOther Res."},{"key":"10.1016\/j.phymed.2026.158065_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115581","article-title":"Curcumin reduces paclitaxel resistance in ovarian carcinoma cells by upregulating SNIP1 and inhibiting nf\u03bab activity","volume":"212","author":"Huang","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phymed.2026.158065_bib0054","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1158\/1078-0432.CCR-23-2864","article-title":"Anti-4-1BB\u00d7PDL1 bispecific antibody reinvigorates tumor-specific exhausted CD8+ T cells and enhances the efficacy of Anti-PD1 blockade","volume":"30","author":"Jeon","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phymed.2026.158065_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110434","article-title":"The impact of quercetin and paclitaxel combination on ovarian cancer cells","volume":"27","author":"Ji","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.phymed.2026.158065_bib0056","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jconrel.2023.11.031","article-title":"Harnessing small extracellular vesicles for pro-oxidant delivery: novel approach for drug-sensitive and resistant cancer therapy","volume":"365","author":"Kang","year":"2024","journal-title":"J. Control Release"},{"key":"10.1016\/j.phymed.2026.158065_bib176","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.21873\/anticanres.13743","article-title":"MLH1 Is a Prognostic Biomarker for Serous Ovarian Cancer Treated With Platinum- and Taxane-based Chemotherapy","volume":"39","author":"Kawashima","year":"2019","journal-title":"Anticancer Res."},{"key":"10.1016\/j.phymed.2026.158065_bib0057","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.3390\/biom10101429","article-title":"Role of glutathione in cancer: from mechanisms to therapies","volume":"10","author":"Kennedy","year":"2020","journal-title":"Biomolecules."},{"key":"10.1016\/j.phymed.2026.158065_bib0058","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/cts.12383","article-title":"Genetic and nongenetic factors affecting clopidogrel response in the Egyptian population","volume":"9","author":"Khalil","year":"2016","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.phymed.2026.158065_bib0059","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.7150\/thno.78171","article-title":"CUB domain-containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy","volume":"12","author":"Khan","year":"2022","journal-title":"Theranostics."},{"key":"10.1016\/j.phymed.2026.158065_bib0060","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3390\/md23040138","article-title":"Marine sponge-derived gukulenin A sensitizes ovarian cancer cells to PARP inhibition via ferroptosis induction","volume":"23","author":"Kim","year":"2025","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.phymed.2026.158065_bib0061","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s43018-023-00617-9","article-title":"Clinical and translational advances in ovarian cancer therapy","volume":"4","author":"Konstantinopoulos","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.phymed.2026.158065_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2025.103830","article-title":"PARP inhibitors in ovarian cancer: mechanisms of resistance and implications to therapy","volume":"149","author":"Kulkarni","year":"2025","journal-title":"DNa Repair. (Amst)"},{"key":"10.1016\/j.phymed.2026.158065_bib0063","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1039\/D2TB02416K","article-title":"LHRH conjugated gold nanoparticles assisted efficient ovarian cancer targeting evaluated via spectral photon-counting CT imaging: a proof-of-concept research","volume":"11","author":"Kumar","year":"2023","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.phymed.2026.158065_bib0065","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/AOG.0000000000004173","article-title":"Updates and new options in advanced epithelial ovarian cancer treatment","volume":"137","author":"Kurnit","year":"2021","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.phymed.2026.158065_bib0066","doi-asserted-by":"crossref","first-page":"m3773","DOI":"10.1136\/bmj.m3773","article-title":"Treatment of epithelial ovarian cancer","volume":"371","author":"Kuroki","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.phymed.2026.158065_bib0067","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.annonc.2022.11.003","article-title":"Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1\/ENGOT-ov25 trial subgroup exploratory analysis","volume":"34","author":"Labidi-Galy","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phymed.2026.158065_bib0068","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12964-025-02146-7","article-title":"Combination therapy with Chicoric acid and PD-1\/PD-L1 blockade improves the immunotherapy response in patient-derived ovarian cancer xenograft model","volume":"23","author":"Lan","year":"2025","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.phymed.2026.158065_bib0069","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1158\/1078-0432.CCR-24-1594","article-title":"Chemotherapy drives tertiary lymphoid structures that correlate with ICI-responsive TCF1+CD8+ T cells in metastatic ovarian cancer","volume":"31","author":"Lanickova","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phymed.2026.158065_bib0070","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.3390\/molecules26061681","article-title":"Theasaponin E1 inhibits platinum-resistant ovarian cancer cells through activating apoptosis and suppressing angiogenesis","volume":"26","author":"Li","year":"2021","journal-title":"Molecules."},{"key":"10.1016\/j.phymed.2026.158065_bib0071","article-title":"MSLN and MUC1 dual-targeting CAR-T with conditional activation and tumor specificity to improve clinical safety and efficacy","volume":"85","author":"Li","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.phymed.2026.158065_bib0072","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.cmet.2023.10.002","article-title":"Tyrosine catabolism enhances genotoxic chemotherapy by suppressing translesion DNA synthesis in epithelial ovarian cancer","volume":"35","author":"Li","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.phymed.2026.158065_bib177","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/path.6055","article-title":"SN-38, an active metabolite of irinotecan, enhances anti-PD-1 treatment efficacy in head and neck squamous cell carcinoma","volume":"259","author":"Lee","year":"2023","journal-title":"J. Pathol."},{"key":"10.1016\/j.phymed.2026.158065_bib0073","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12951-022-01264-5","article-title":"Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer","volume":"20","author":"Li","year":"2022","journal-title":"J. Nanobiotechnology."},{"key":"10.1016\/j.phymed.2026.158065_bib0077","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/jpp\/rgaf006","article-title":"Natural product pulsatilla saponin D sensitizes BRCA-proficient ovarian cancers to PARP inhibitors through inhibiting homologous recombination repair","volume":"77","author":"Lin","year":"2025","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.phymed.2026.158065_bib0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115897","article-title":"Polycomb repressor complex: its function in human cancer and therapeutic target strategy","volume":"169","author":"Liu","year":"2023","journal-title":"Biomed. PharmacOther"},{"key":"10.1016\/j.phymed.2026.158065_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216700","article-title":"STING inhibitors sensitize platinum chemotherapy in ovarian cancer by inhibiting the CGAS-STING pathway in cancer-associated fibroblasts (CAFs)","volume":"588","author":"Liu","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phymed.2026.158065_bib0080","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3390\/pharmaceutics16060744","article-title":"Effects of surface IR783 density on the In vivo behavior and imaging performance of liposomes","volume":"16","author":"Long","year":"2024","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.phymed.2026.158065_bib0081","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1083\/jcb.201102147","article-title":"The extracellular matrix: a dynamic niche in cancer progression","volume":"196","author":"Lu","year":"2012","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.phymed.2026.158065_bib0082","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110401","article-title":"The contribution of copper efflux transporters ATP7A and ATP7B to chemoresistance and personalized medicine in ovarian cancer","volume":"129","author":"Lukanovi\u0107","year":"2020","journal-title":"Biomed. PharmacOther"},{"key":"10.1016\/j.phymed.2026.158065_bib0083","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1016\/j.cell.2024.06.013","article-title":"Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector treg cells for homologous-recombination-deficient tumors","volume":"187","author":"Luo","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.phymed.2026.158065_bib0084","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1254532","article-title":"Therapeutic strategies targeting folate receptor \u03b1 for ovarian cancer","volume":"14","author":"Mai","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phymed.2026.158065_bib0085","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.talanta.2013.05.016","article-title":"A novel method for speciation of Pt in human serum incubated with cisplatin, oxaliplatin and carboplatin by conjoint liquid chromatography on monolithic disks with UV and ICP-MS detection","volume":"116","author":"Martin\u010di\u010d","year":"2013","journal-title":"Talanta"},{"key":"10.1016\/j.phymed.2026.158065_bib0086","first-page":"781","article-title":"[Senescence and Cancer]","volume":"51","author":"Matsumoto","year":"2024","journal-title":"Gan. To Kagaku Ryoho"},{"key":"10.1016\/j.phymed.2026.158065_bib0087","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/PAT.0b013e328348a6e7","article-title":"Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis","volume":"43","author":"McCluggage","year":"2011","journal-title":"Pathology."},{"key":"10.1016\/j.phymed.2026.158065_bib0088","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s13048-023-01308-w","article-title":"The effect of paclitaxel- and fisetin-loaded PBM nanoparticles on apoptosis and reversal of drug resistance gene ABCG2 in ovarian cancer","volume":"16","author":"McFadden","year":"2023","journal-title":"J. Ovarian. Res."},{"key":"10.1016\/j.phymed.2026.158065_bib0089","doi-asserted-by":"crossref","first-page":"7091","DOI":"10.1016\/j.cell.2024.10.020","article-title":"STK19 positions TFIIH for cell-free transcription-coupled DNA repair","volume":"187","author":"Mevissen","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.phymed.2026.158065_bib0090","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s13402-016-0289-1","article-title":"Ovarian cancer-derived ascitic fluids induce a senescence-dependent pro-cancerogenic phenotype in normal peritoneal mesothelial cells","volume":"39","author":"Miku\u0142a-Pietrasik","year":"2016","journal-title":"Cell Oncol. (Dordr)"},{"key":"10.1016\/j.phymed.2026.158065_bib0091","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","article-title":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer","volume":"31","author":"Miller","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phymed.2026.158065_bib0092","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1039\/D2NP00091A","article-title":"Discovery and development of botanical natural products and their analogues as therapeutics for ovarian cancer","volume":"40","author":"Mize","year":"2023","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.phymed.2026.158065_bib0093","doi-asserted-by":"crossref","first-page":"7492","DOI":"10.1016\/j.cell.2024.10.006","article-title":"Ovarian cancer-derived IL-4 promotes immunotherapy resistance","volume":"187","author":"Mollaoglu","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.phymed.2026.158065_bib0094","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12943-024-02020-z","article-title":"Aging and cancer","volume":"23","author":"Mont\u00e9gut","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.phymed.2026.158065_bib0095","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/iub.1510","article-title":"Effect of vildagliptin and pravastatin combination on cholesterol efflux in adipocytes","volume":"68","author":"Mostafa","year":"2016","journal-title":"IUBMB Life"},{"key":"10.1016\/j.phymed.2026.158065_bib0096","doi-asserted-by":"crossref","first-page":"9981","DOI":"10.3390\/ijms23179981","article-title":"The proteolytic landscape of ovarian cancer: applications in nanomedicine","volume":"23","author":"O\u2019Connell","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phymed.2026.158065_bib0097","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s41232-022-00197-8","article-title":"The roles and mechanisms of senescence-associated secretory phenotype (SASP): can it be controlled by senolysis?","volume":"42","author":"Ohtani","year":"2022","journal-title":"Inflamm. Regen."},{"key":"10.1016\/j.phymed.2026.158065_bib0098","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11523-023-00970-w","article-title":"PARP Inhibitors in ovarian cancer: a review","volume":"18","author":"O\u2019Malley","year":"2023","journal-title":"Target. Oncol."},{"key":"10.1016\/j.phymed.2026.158065_bib0099","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115816","article-title":"A natural product, voacamine, sensitizes paclitaxel-resistant human ovarian cancer cells","volume":"434","author":"Pellegrini","year":"2022","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.phymed.2026.158065_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110376","article-title":"Astragalus polysaccharides sensitize ovarian cancer stem cells to PARPi by inhibiting mitophagy via PINK1\/Parkin signaling","volume":"27","author":"Peng","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.phymed.2026.158065_bib0101","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1038\/s41467-021-24009-8","article-title":"Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance","volume":"12","author":"Pietil\u00e4","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phymed.2026.158065_bib0102","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phymed.2026.158065_bib0103","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146186","article-title":"Cancer-associated mesothelial cells promote ovarian cancer chemoresistance through paracrine osteopontin signaling","volume":"131","author":"Qian","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phymed.2026.158065_bib0104","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/649161","article-title":"The role of extracellular vesicles: an epigenetic view of the cancer microenvironment","volume":"2015","author":"Qian","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.phymed.2026.158065_bib0105","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.cmet.2025.06.002","article-title":"Microbial riboflavin inhibits ceramide synthase 3 to lower ceramide (d18:1\/26:0) and delay colorectal cancer progression","volume":"37","author":"Qu","year":"2025","journal-title":"Cell Metab."},{"key":"10.1016\/j.phymed.2026.158065_bib0106","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phymed.2026.158065_bib0107","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.canlet.2021.05.001","article-title":"Resveratrol for cancer therapy: challenges and future perspectives","volume":"515","author":"Ren","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phymed.2026.158065_bib0108","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1158\/1078-0432.CCR-24-1225","article-title":"Effectiveness of PARP inhibitor maintenance therapy in ovarian cancer by BRCA1\/2 and a scar-based HRD signature in real-world practice","volume":"30","author":"Richardson","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phymed.2026.158065_bib0109","article-title":"Safety of bevacizumab and olaparib as frontline maintenance therapy in advanced ovarian cancer: expert review for clinical practice","volume":"13","author":"Romero","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phymed.2026.158065_bib0110","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1158\/1535-7163.MCT-05-0102","article-title":"Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells","volume":"4","author":"Safaei","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phymed.2026.158065_bib0111","article-title":"Epithelial ovarian cancer: review article","volume":"33","author":"Sambasivan","year":"2022","journal-title":"Cancer Treat. Res. Commun."},{"key":"10.1016\/j.phymed.2026.158065_bib0112","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1158\/0008-5472.CAN-20-2701","article-title":"Mesothelin-specific CAR T cells target ovarian cancer","volume":"81","author":"Schoutrop","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.phymed.2026.158065_bib0113","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202302547RR","article-title":"Procyanidin C1 inhibits bleomycin-induced pulmonary fibrosis in mice by selective clearance of senescent myofibroblasts","volume":"38","author":"Shao","year":"2024","journal-title":"FASEB J."},{"key":"10.1016\/j.phymed.2026.158065_bib0114","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.phymed.2026.158065_bib0116","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41419-025-07430-5","article-title":"MicroRNA-379-5p attenuates cancer stem cells and reduces cisplatin resistance in ovarian cancer by regulating RAD18\/pol\u03b7 axis","volume":"16","author":"Shukla","year":"2025","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.phymed.2026.158065_bib0117","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/0113816128277350231219062154","article-title":"Differential signaling pathways in medulloblastoma: nano-biomedicine targeting non-coding epigenetics to improve current and future therapeutics","volume":"30","author":"Sokolov","year":"2024","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phymed.2026.158065_bib0118","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1038\/s41467-020-20140-0","article-title":"Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages","volume":"11","author":"Song","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phymed.2026.158065_bib0119","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/biomedicines10010082","article-title":"DNA damage repair: predictor of platinum efficacy in ovarian cancer?","volume":"10","author":"Stefanou","year":"2021","journal-title":"Biomedicines."},{"key":"10.1016\/j.phymed.2026.158065_bib0120","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/oncolo\/oyab053","article-title":"Homologous recombination deficiency: concepts, definitions, and assays","volume":"27","author":"Stewart","year":"2022","journal-title":"Oncologist."},{"key":"10.1016\/j.phymed.2026.158065_bib0121","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1200\/JCO.20.01924","article-title":"PARP inhibitors in the management of ovarian cancer: ASCO guideline","volume":"38","author":"Tew","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phymed.2026.158065_bib0122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2019.12.008","article-title":"Natural products targeting the PI3K-akt-mTOR signaling pathway in cancer: a novel therapeutic strategy","volume":"80","author":"Tewari","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.phymed.2026.158065_bib0123","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ygyno.2025.04.578","article-title":"OVATION-2: a randomized phase I\/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo\/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer","volume":"197","author":"Thaker","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.phymed.2026.158065_bib0124","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41419-022-04510-8","article-title":"Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion","volume":"13","author":"Tian","year":"2022","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.phymed.2026.158065_bib0125","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2021.747956","article-title":"Curcumin extraction, isolation, quantification and its application in functional foods: a review with a focus on immune enhancement activities and COVID-19","volume":"8","author":"Tripathy","year":"2021","journal-title":"Front. Nutr."},{"key":"10.1016\/j.phymed.2026.158065_bib0126","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1001\/jamaoncol.2021.0580","article-title":"Hyperthermic intraperitoneal chemotherapy for ovarian and colorectal cancer: a review","volume":"7","author":"van Stein","year":"2021","journal-title":"JAMa Oncol."},{"key":"10.1016\/j.phymed.2026.158065_bib0127","doi-asserted-by":"crossref","first-page":"C125","DOI":"10.1152\/ajpcell.00049.2022","article-title":"The senescence-associated secretory phenotype in ovarian cancer dissemination","volume":"323","author":"Veenstra","year":"2022","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.phymed.2026.158065_bib0128","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.annonc.2021.11.013","article-title":"European experts consensus: bRCA\/homologous recombination deficiency testing in first-line ovarian cancer","volume":"33","author":"Vergote","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phymed.2026.158065_bib0129","article-title":"Senescence-associated secretory phenotype regulation by dual drug delivery biomimetic nanoplatform for enhanced tumor chemotherapy","volume":"32","author":"Wang","year":"2024","journal-title":"Mol Ther Oncol"},{"key":"10.1016\/j.phymed.2026.158065_bib0130","article-title":"Therapeutic prospects of polysaccharides for ovarian cancer","volume":"9","author":"Wang","year":"2022","journal-title":"Front. Nutr."},{"key":"10.1016\/j.phymed.2026.158065_bib0134","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108374","article-title":"Metallothionein-2: an emerging target in inflammatory diseases and cancers","volume":"244","author":"Wang","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.phymed.2026.158065_bib0136","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1186\/s12967-025-06508-0","article-title":"Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements","volume":"23","author":"Wang","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.phymed.2026.158065_bib0138","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1158\/1078-0432.CCR-21-2096","article-title":"Pan-cancer analysis of homologous recombination repair-associated gene alterations and genome-wide loss-of-heterozygosity score","volume":"28","author":"Westphalen","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phymed.2026.158065_bib0139","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1186\/s12964-024-01806-4","article-title":"Adipocyte derived exosomes promote cell invasion and challenge paclitaxel efficacy in ovarian cancer","volume":"22","author":"Williams","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.phymed.2026.158065_bib0140","doi-asserted-by":"crossref","first-page":"e2134","DOI":"10.1002\/biof.2134","article-title":"Piperine: an emerging biofactor with anticancer efficacy and therapeutic potential","volume":"51","author":"Wiraswati","year":"2025","journal-title":"Biofactors"},{"key":"10.1016\/j.phymed.2026.158065_bib0141","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.3390\/ijms22084243","article-title":"Piperine targets different drug resistance mechanisms in Human ovarian cancer cell lines leading to increased sensitivity to cytotoxic drugs","volume":"22","author":"Wojtowicz","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phymed.2026.158065_bib0142","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fonc.2017.00024","article-title":"The unique molecular and cellular microenvironment of ovarian cancer","volume":"7","author":"Worzfeld","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phymed.2026.158065_bib0143","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.3390\/molecules26195949","article-title":"Mechanisms and advances in anti-ovarian cancer with natural plants component","volume":"26","author":"Wu","year":"2021","journal-title":"Molecules."},{"key":"10.1016\/j.phymed.2026.158065_bib0144","article-title":"KLF5 Promotes tumor progression and parp inhibitor resistance in ovarian cancer","volume":"10","author":"Wu","year":"2023","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.phymed.2026.158065_bib0145","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1189015","article-title":"Cellular senescence: a double-edged sword in cancer therapy","volume":"13","author":"Xiao","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phymed.2026.158065_bib0146","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1265525","article-title":"Metabolic and senescence characteristics associated with the immune microenvironment in ovarian cancer","volume":"14","author":"Xiong","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.phymed.2026.158065_bib0147","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.3390\/molecules27144523","article-title":"Anticancer effects and mechanisms of berberine from medicinal herbs: an update review","volume":"27","author":"Xiong","year":"2022","journal-title":"Molecules."},{"key":"10.1016\/j.phymed.2026.158065_bib180","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s42255-021-00491-8","article-title":"The flavonoid procyanidin C1 has senotherapeutic activity and increases lifespan in mice","volume":"3","author":"Xu","year":"2021","journal-title":"Nat. Metab."},{"key":"10.1016\/j.phymed.2026.158065_bib0148","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1142\/S0192415X25500247","article-title":"Ginsenoside Rg6 improves cisplatin resistance in epithelial ovarian cancer cells via suppressing fucosylation and inducing autophagy","volume":"53","author":"Xue","year":"2025","journal-title":"Am. J. Chin. Med."},{"key":"10.1016\/j.phymed.2026.158065_bib0149","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.156121","article-title":"Berberine modulates ovarian cancer autophagy and glycolysis through the LINC01123\/P65\/MAPK10 signaling axis","volume":"135","author":"Yan","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.phymed.2026.158065_bib0150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.577869","article-title":"Immunotherapy for ovarian cancer: adjuvant, combination, and neoadjuvant","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phymed.2026.158065_bib0151","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3892\/or.2022.8293","article-title":"Molecular mechanisms of platinum\u2011based chemotherapy resistance in ovarian cancer (Review)","volume":"47","author":"Yang","year":"2022","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.phymed.2026.158065_bib0152","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/jcp.25349","article-title":"Mitochondria and mitochondrial ROS in cancer: novel targets for anticancer therapy","volume":"231","author":"Yang","year":"2016","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.phymed.2026.158065_bib0153","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.1038\/s41467-021-24315-1","article-title":"Extracellular matrix protein-1 secretory isoform promotes ovarian cancer through increasing alternative mRNA splicing and stemness","volume":"12","author":"Yin","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phymed.2026.158065_bib0154","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.22.01207","article-title":"Identification of patients with ovarian cancer experiencing the highest benefit from Bevacizumab in the first-line setting on the basis of their tumor-intrinsic chemosensitivity (KELIM): the GOG-0218 validation study","volume":"40","author":"You","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phymed.2026.158065_bib0156","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3390\/cells13151245","article-title":"A comprehensive insight and In silico analysis of CircRNAs in hepatocellular carcinoma: a step toward ncRNA-based precision medicine","volume":"13","author":"Youness","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.phymed.2026.158065_bib0157","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.136678","article-title":"Targeting ATP catalytic activity of chromodomain helicase CHD1L for the anticancer inhibitor discovery","volume":"281","author":"Zhang","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.phymed.2026.158065_bib0159","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1002\/ptr.70021","article-title":"Targeting CDK9 with harmine induces homologous recombination deficiency and synergizes with PARP inhibitors in ovarian cancer","volume":"39","author":"Zhang","year":"2025","journal-title":"PhytOther Res."},{"key":"10.1016\/j.phymed.2026.158065_bib0160","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/cac2.12163","article-title":"Structural and functional characterization of multiple myeloma associated cytoplasmic poly(A) polymerase FAM46C","volume":"41","author":"Zhang","year":"2021","journal-title":"Cancer Commun. (Lond)"},{"key":"10.1016\/j.phymed.2026.158065_bib0161","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1142\/S0192415X23500234","article-title":"Dihydroartemisinin affects STAT3\/DDA1 signaling pathway and reverses breast cancer resistance to cisplatin","volume":"51","author":"Zhang","year":"2023","journal-title":"Am. J. Chin. Med."},{"key":"10.1016\/j.phymed.2026.158065_bib0170","first-page":"1","article-title":"T cell exhaustion and senescence for ovarian cancer immunotherapy","volume":"104\u2013105","author":"Zhao","year":"2024","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.phymed.2026.158065_bib0171","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173887","article-title":"Berberine inhibits chemotherapy-exacerbated ovarian cancer stem cell-like characteristics and metastasis through GLI1","volume":"895","author":"Zhao","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phymed.2026.158065_bib0172","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105066","article-title":"Bioactive sesquiterpenes from Inula helenium","volume":"114","author":"Zheng","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.phymed.2026.158065_bib0173","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1186\/s12964-024-01977-0","article-title":"GG-NER\u2019s role in androgen receptor signaling inhibitor response for advanced prostate cancer","volume":"22","author":"Zhong","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.phymed.2026.158065_bib179","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1186\/s12951-024-02744-6","article-title":"Tumor targeting peptide TMTP1 modified Antigen capture Nano-vaccine combined with chemotherapy and PD-L1 blockade effectively inhibits growth of ovarian cancer","volume":"22","author":"Zhou","year":"2024","journal-title":"J. Nanobiotechn."},{"key":"10.1016\/j.phymed.2026.158065_bib0174","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jare.2022.09.007","article-title":"Paclitaxel-loaded ginsenoside Rg3 liposomes for drug-resistant cancer therapy by dual targeting of the tumor microenvironment and cancer cells","volume":"49","author":"Zhu","year":"2023","journal-title":"J. Adv. Res."}],"container-title":["Phytomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711326003016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711326003016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:08:49Z","timestamp":1790114929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0944711326003016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":157,"alternative-id":["S0944711326003016"],"URL":"https:\/\/doi.org\/10.1016\/j.phymed.2026.158065","relation":{},"ISSN":["0944-7113"],"issn-type":[{"value":"0944-7113","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plant-derived natural compounds targeting drug resistance in ovarian cancer: Molecular mechanisms and therapeutic perspectives","name":"articletitle","label":"Article Title"},{"value":"Phytomedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phymed.2026.158065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"158065"}}